Improving CAR T cell therapy for brain cancer with tiny drug carriers
Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells
This project aims to create a new way to deliver medicine directly to brain tumors using special immune cells, hoping to make treatments more effective for adults with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11129897 on NIH RePORTER |
What this research studies
Glioblastoma is a very serious brain cancer with limited treatment options, and current CAR T cell therapies, which use a patient's own immune cells to fight cancer, face challenges in solid tumors like glioblastoma due to the tumor's protective environment. This project plans to develop a new method to load these CAR T cells with tiny drug carriers. These carriers would help the CAR T cells overcome the tumor's defenses, making the treatment more powerful and reducing side effects in other parts of the body.
Who could benefit from this research
Good fit: This research is ultimately intended for adult patients diagnosed with glioblastoma multiforme, especially those for whom current treatments are not curative.
Not a fit: Patients with other types of cancer or those who are not adults may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this approach could lead to a new, more effective, and less toxic targeted therapy for glioblastoma patients, potentially improving survival rates.
How similar studies have performed: While CAR T cell therapies have shown promise in other cancers, their success in solid tumors like glioblastoma has been limited, making this approach to overcome tumor defenses a novel strategy.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Akhavan, David — University of Kansas Medical Center
- Study coordinator: Akhavan, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.